Estimated impact on birth weight of scaling up intermittent preventive treatment of malaria in pregnancy given sulphadoxine-pyrimethamine resistance in Africa: A mathematical model

English version České info

Background:
Malaria transmission has declined substantially in the 21st century, but pregnant women in areas of sustained transmission still require protection to prevent the adverse pregnancy and birth outcomes associated with malaria in pregnancy (MiP). A recent call to action has been issued to address the continuing low coverage of intermittent preventive treatment of malaria in pregnancy (IPTp). This call has, however, been questioned by some, in part due to concerns about resistance to sulphadoxine-pyrimethamine (SP), the only drug currently recommended for IPTp.

Methods and findings:
Using an existing mathematical model of MiP, we combined estimates of the changing endemicity of malaria across Africa with maps of SP resistance mutations and current coverage of antenatal access and IPTp with SP (IPTp-SP) across Africa. Using estimates of the relationship between SP resistance mutations and the parasitological efficacy of SP during pregnancy, we estimated the varying impact of IPTp-SP across Africa and the incremental value of enhancing IPTp-SP uptake to match current antenatal care (ANC) coverage.

The risks of MiP and malaria-attributable low birthweight (mLBW) in unprotected pregnancies (i.e., those not using insecticide-treated nets [ITNs]) leading to live births fell by 37% (33%–41% 95% credible interval [crI]) and 31% (27%–34% 95% crI), respectively, from 2000 to 2015 across endemic areas in sub-Saharan Africa. However, these gains are fragile, and coverage is far from optimal. In 2015, 9.5 million (8.3 million–10.4 million 95% crI) of 30.6 million pregnancies in these areas would still have been infected with Plasmodium falciparum without intervention, leading to 750,000 (390,000–1.1 million 95% crI) mLBW deliveries. In all, 6.6 million (5.6 million–7.3 million 95% crI) of these 9.5 million (69.3%) pregnancies at risk of infection (and 53.4% [16.3 million/30.6 million] of all pregnancies) occurred in settings with near-perfect SP curative efficacy (>99%) based on the most recent estimates of resistance. Forty-four percent of these pregnancies (23% of all pregnancies) were not receiving any IPTp-SP despite making ≥3 ANC visits, representing 160,000 (94,000–236,000 95% crI) preventable low birthweight (LBW) deliveries. Only 4% (1.4 million) of pregnancies occurred in settings with >10% prevalence of the sextuple haplotype associated with compromised SP effectiveness. Forty-two percent of all pregnancies occurred in settings where the quintuple dhfr/dhps haplotype had become established but where in vivo efficacy data suggest SP maintains the majority of its effectiveness in clearing infections.

Not accounting for protection from the use of ITNs during pregnancy, expanding IPTp-SP to all women with ≥3 ANC visits in Africa could prevent an additional 215,000 (128,000–318,000 95% crI) LBW deliveries. In 26 countries with sufficient recent data to estimate ITN impact (population-based ITN usage data that can be stratified by gravidity), we estimate that, due primarily to low ITN use by primigravidae, only 16.5% of the potential LBW births prevented by scaling up IPTp-SP would in fact have already have been prevented through ITN use.

Our analysis also highlights the difficulties associated with estimating the relationship between the effectiveness of interventions against parasitological endpoints such as placental infection at delivery and health outcomes including birthweight, which is also determined by a wide range of unrelated factors. We also did not capture other aspects of malaria burden such as clinical malaria, maternal and neonatal anaemia, and miscarriage, all of which increase the overall importance of effective preventative strategies but have their own relationship with transmission intensity, parity, and SP resistance.

Conclusions:
Despite recent declines in malaria transmission in Africa, the burden of MiP in the absence of adequate prevention remains substantial. Even accounting for SP resistance, extending IPTp-SP to all women attending ANC, as well as long-lasting insecticidal net distribution targeted towards first-time mothers, would have a sizeable impact upon maternal and infant health in almost all malaria-endemic settings in sub-Saharan Africa.

Vyšlo v časopise: Estimated impact on birth weight of scaling up intermittent preventive treatment of malaria in pregnancy given sulphadoxine-pyrimethamine resistance in Africa: A mathematical model. PLoS Med 14(2): e32767. doi:10.1371/journal.pmed.1002243
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1002243

Souhrn

Zdroje

1. Alonso PL, Tanner M. Public health challenges and prospects for malaria control and elimination. Nat Med. 2013;19:150–5. doi: 10.1038/nm.3077 23389615

2. Steketee RW, Nahlen BL, Parise ME, Menendez C. The burden of malaria in pregnancy in malaria-endemic areas. Am J Trop Med Hyg. 2001;64:28.

3. Guyatt HL, Snow RW. Impact of malaria during pregnancy on low birth weight in sub-Saharan Africa. Clin Microbiol Rev. 2004;17:760–9. doi: 10.1128/CMR.17.4.760-769.2004 15489346

4. Guyatt HL, Snow RW. Malaria in pregnancy as an indirect cause of infant mortality in sub-Saharan Africa. Trans R Soc Trop Med Hyg. 2001;95:569–76. 11816423

5. Bhatt S, Weiss DJ, Cameron E, Bisanzio D, Mappin B, Dalrymple U, et al. The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015. Nature. 2015;526:207–11. doi: 10.1038/nature15535 26375008

6. World Health Organization. World Malaria Report 2015. Geneva: World Health Organization; 2015 [cited 2017 Jan 26]. Available from: http://www.who.int/malaria/publications/world-malaria-report-2015/report/en/.

7. Desai M, ter Kuile FO, Nosten F, McGready R, Asamoa K, Brabin B, et al. Epidemiology and burden of malaria in pregnancy. Lancet Infect Dis. 2007;7:93–104. doi: 10.1016/S1473-3099(07)70021-X 17251080

8. Van Eijk AM, Ayisi JG, ter Kuile FO, Otieno JA, Misore AO, Odondi JO, et al. Effectiveness of intermittent preventive treatment with sulphadoxine-pyrimethamine for control of malaria in pregnancy in western Kenya: a hospital-based study. Trop Med Int Health. 2004;9:351–60. 14996364

9. Kayentao K, Garner P, van Eijk AM, Naidoo I, Roper C, Mulokozi A, et al. Intermittent preventive therapy for malaria during pregnancy using 2 vs 3 or more doses of sulfadoxine-pyrimethamine and risk of low birth weight in Africa: systematic review and meta-analysis. JAMA. 2013;309:594–604. doi: 10.1001/jama.2012.216231 23403684

10. Eisele TP, Larsen DA, Anglewicz PA, Keating J, Yukich J, Bennett A, et al. Malaria prevention in pregnancy, birthweight, and neonatal mortality: a meta-analysis of 32 national cross-sectional datasets in Africa. Lancet Infect Dis. 2012;12:942–9. doi: 10.1016/S1473-3099(12)70222-0 22995852

11. Ter Kuile FO, van Eijk AM, Filler SJ. Effect of sulfadoxine-pyrimethamine resistance on the efficacy of intermittent preventive therapy for malaria control during pregnancy: a systematic review. JAMA. 2007;297:2603–16. doi: 10.1001/jama.297.23.2603 17579229

12. Fernandes S, Sicuri E, Kayentao K, van Eijk AM, Hill J, Webster J, et al. Cost-effectiveness of two versus three or more doses of intermittent preventive treatment for malaria during pregnancy in sub-Saharan Africa: a modelling study of meta-analysis and cost data. Lancet Glob Heal. 2015;3:e143–53.

13. Walker PGT, ter Kuile FO, Garske T, Menendez C, Ghani AC. Estimated risk of placental infection and low birthweight attributable to Plasmodium falciparum malaria in Africa in 2010: a modelling study. Lancet Glob Heal. 2014;2:e460–7.

14. Van Eijk AM, Hill J, Larsen DA, Webster J, Steketee RW, Eisele TP, et al. Coverage of intermittent preventive treatment and insecticide-treated nets for the control of malaria during pregnancy in sub-Saharan Africa: a synthesis and meta-analysis of national survey data, 2009–11. Lancet Infect Dis. 2013;13(12):1029–42. doi: 10.1016/S1473-3099(13)70199-3 24054085

15. Chico RM, Dellicour S, Roman E, Mangiaterra V, Coleman J, Menendez C, et al. Global Call to Action: maximize the public health impact of intermittent preventive treatment of malaria in pregnancy in sub-Saharan Africa. Malar J. 2015;14:207. doi: 10.1186/s12936-015-0728-x 25986063

16. Nosten F, McGready R. Intermittent presumptive treatment in pregnancy with sulfadoxine-pyrimethamine: a counter perspective. Malar J. 2015;14:248. doi: 10.1186/s12936-015-0765-5 26088554

17. Harrington W, McGready R, Muehlenbachs A, Fried M, Nosten F, Duffy P. Intermittent preventive treatment in pregnancy with sulfadoxine-pyrimethamine: the times they are a-changin’. Clin Infect Dis. 2012;55:1025–6. doi: 10.1093/cid/cis568 22715177

18. Harrington WE, Fried M, Duffy PE. Defending the use of sulfadoxine-pyrimethamine for intermittent preventive treatment for malaria in pregnancy: a short-sighted strategy. J Infect Dis. 2015;213(3):496–7. doi: 10.1093/infdis/jiv420 26290607

19. Mugittu K, Abdulla S, Falk N, Masanja H, Felger I, Mshinda H, et al. Efficacy of sulfadoxine-pyrimethamine in Tanzania after two years as first-line drug for uncomplicated malaria: assessment protocol and implication for treatment policy strategies. Malar J. 2005;4:55. doi: 10.1186/1475-2875-4-55 16297234

20. Griffin JT, Cairns M, Ghani AC, Roper C, Schellenberg D, Carneiro I, et al. Protective efficacy of intermittent preventive treatment of malaria in infants (IPTi) using sulfadoxine-pyrimethamine and parasite resistance. PLoS ONE. 2010;5:e12618. doi: 10.1371/journal.pone.0012618 20838642

21. Naidoo I, Roper C. Mapping “partially resistant”, “fully resistant”, and “super resistant” malaria. Trends Parasitol. 2013;29:505–15. doi: 10.1016/j.pt.2013.08.002 24028889

22. Desai M, Gutman J, Taylor SM, Wiegand RE, Khairallah C, Kayentao K, et al. Impact of sulfadoxine-pyrimethamine resistance on effectiveness of intermittent preventive therapy for malaria in pregnancy at clearing infections and preventing low birth weight. Clin Infect Dis. 2016;62:323–33. doi: 10.1093/cid/civ881 26486699

23. Harrington WE, Mutabingwa TK, Kabyemela E, Fried M, Duffy PE. Intermittent treatment to prevent pregnancy malaria does not confer benefit in an area of widespread drug resistance. Clin Infect Dis. 2011;53:224–30. doi: 10.1093/cid/cir376 21765070

24. Gutman J, Kalilani L, Taylor S, Zhou Z, Wiegand RE, Thwai KL, et al. Plasmodium falciparum dihydropteroate synthetase-A581G mutation reduces effectiveness of sulfadoxine-pyrimethamine preventive therapy in Malawian pregnant women. J Infect Dis. 2015;211(12):1997–2005. doi: 10.1093/infdis/jiu836 25564249

25. Harrington WE, Mutabingwa TK, Muehlenbachs A, Sorensen B, Bolla MC, Fried M, et al. Competitive facilitation of drug-resistant Plasmodium falciparum malaria parasites in pregnant women who receive preventive treatment. Proc Natl Acad Sci U S A. 2009;106:9027–32. doi: 10.1073/pnas.0901415106 19451638

26. Wolfe EB, Parise ME, Haddix AC, Nahlen BL, Ayisi JG, Misore A, et al. Cost-effectiveness of sulfadoxine-pyrimethamine for the prevention of malaria-associated low birth weight. Am J Trop Med Hyg. 64:178–86. 11442215

27. Mbonye AK, Hansen KS, Bygbjerg IC, Magnussen P. Intermittent preventive treatment of malaria in pregnancy: the incremental cost-effectiveness of a new delivery system in Uganda. Trans R Soc Trop Med Hyg. 2008;102:685–93. doi: 10.1016/j.trstmh.2008.04.016 18513767

28. Hansen KS, Ndyomugyenyi R, Magnussen P, Clarke SE. Cost-effectiveness analysis of three health interventions to prevent malaria in pregnancy in an area of low transmission in Uganda. Int Health. 2012;4:38–46. doi: 10.1016/j.inhe.2011.10.001 24030879

29. Flegg JA, Patil AP, Venkatesan M, Roper C, Naidoo I, Hay SI, et al. Spatiotemporal mathematical modelling of mutations of the dhps gene in African Plasmodium falciparum. Malar J. 2013;12:249. doi: 10.1186/1475-2875-12-249 23866695

30. The DHS Program: Demographic and Health Surveys. Rockville (Maryland): ICF International; 2017 [cited 2017 Feb 2]. Available from: http://dhsprogram.com/

31. Oak Ridge National Laboratory. LandScan. Oak Ridge (Tennessee): Oak Ridge National Laboratory; 2017 [cited 2017 Feb 2]. Available from: http://www.ornl.gov/sci/landscan/.

32. Population prospects for the twenty-first century: the 2010 United Nations projections. Popul Dev Rev. 2011;37:407–11.

33. Walker PGT, Griffin JT, Cairns M, Rogerson SJ, van Eijk AM, Ter Kuile F, et al. A model of parity-dependent immunity to placental malaria. Nat Commun. 2013;4:1609. doi: 10.1038/ncomms2605 23511473

34. Van Eijk AM, Hill J, Alegana VA, Kirui V, Gething PW, Ter Kuile FO, et al. Coverage of malaria protection in pregnant women in sub-Saharan Africa: a synthesis and analysis of national survey data. Lancet Infect Dis. 2011;11:190–207. doi: 10.1016/S1473-3099(10)70295-4 21273130

35. Kayentao K, Kodio M, Newman RD, Maiga H, Doumtabe D, Ongoiba A, et al. Comparison of intermittent preventive treatment with chemoprophylaxis for the prevention of malaria during pregnancy in Mali. J Infect Dis. 2005;191:109–16. doi: 10.1086/426400 15593011

36. Challis K, Osman NB, Cotiro M, Nordahl G, Dgedge M, Bergström S. Impact of a double dose of sulphadoxine-pyrimethamine to reduce prevalence of pregnancy malaria in southern Mozambique. Trop Med Int Health. 2004;9:1066–73. doi: 10.1111/j.1365-3156.2004.01307.x 15482398

37. Parise ME, Ayisi JG, Nahlen BL, Schultz LJ, Roberts JM, Misore A, et al. Efficacy of sulfadoxine-pyrimethamine for prevention of placental malaria in an area of Kenya with a high prevalence of malaria and human immunodeficiency virus infection. Am J Trop Med Hyg. 1998;59:813–22. 9840604

38. Njagi JK, Magnussen P, Estambale B, Ouma J, Mugo B. Prevention of anaemia in pregnancy using insecticide-treated bednets and sulfadoxine-pyrimethamine in a highly malarious area of Kenya: a randomized controlled trial. Trans R Soc Trop Med Hyg. 97:277–82. 15228241

39. Schultz LJ, Steketee RW, Macheso A, Kazembe P, Chitsulo L, Wirima JJ. The efficacy of antimalarial regimens containing sulfadoxine-pyrimethamine and/or chloroquine in preventing peripheral and placental Plasmodium falciparum infection among pregnant women in Malawi. Am J Trop Med Hyg. 1994;51:515–22. 7985742

40. Ter Kuile FO, Terlouw DJ, Phillips-Howard PA, Hawley WA, Friedman JF, Kariuki SK, et al. Reduction of malaria during pregnancy by permethrin-treated bed nets in an area of intense perennial malaria transmission in western Kenya. Am J Trop Med Hyg. 2003;68:50–60. 12749486

41. Njagi JK. The effects of sulfadoxine-pyrimethamine intermittent treatment and pyrethroid impregnated bed nets on malaria morbidity and birth weight in Bondo district, Kenya [dissertation]. Nairobi: University of Nairobi; 2002.

42. Gamble C, Ekwaru PJ, Garner P, ter Kuile FO. Insecticide-treated nets for the prevention of malaria in pregnancy: a systematic review of randomised controlled trials. PLoS Med. 2007;4:e107. doi: 10.1371/journal.pmed.0040107 17388668

43. Cairns M, Carneiro I, Milligan P, Owusu-Agyei S, Awine T, Gosling R, et al. Duration of protection against malaria and anaemia provided by intermittent preventive treatment in infants in Navrongo, Ghana. PLoS ONE. 2008;3:e2227. doi: 10.1371/journal.pone.0002227 18493597

44. Walker PGT, ter Kuile FO, Garske T, Menendez C, Ghani AC. Estimated risk of placental infection and low birthweight attributable to Plasmodium falciparum malaria in Africa in 2010: a modelling study. Lancet Glob Heal. 2014;2:e460–7.

45. Mayor A, Bardají A, Macete E, Nhampossa T, Fonseca AM, González R, et al. Changing trends in P. falciparum burden, immunity, and disease in pregnancy. N Engl J Med. 2015;373:1607–17. doi: 10.1056/NEJMoa1406459 26488692

46. Menéndez C, Bardají A, Sigauque B, Romagosa C, Sanz S, Serra-Casas E, et al. A randomized placebo-controlled trial of intermittent preventive treatment in pregnant women in the context of insecticide treated nets delivered through the antenatal clinic. PLoS ONE. 2008;3:e1934. doi: 10.1371/journal.pone.0001934 18398460

47. Minja DTR, Schmiegelow C, Mmbando B, Boström S, Oesterholt M, Magistrado P, et al. Plasmodium falciparum mutant haplotype infection during pregnancy associated with reduced birthweight, Tanzania. Emerg Infect Dis. 2013;19.